What's moving these stocks in the pre-market hours today? In the Green 1. Miragen Therapeutics Inc. (MGEN) is up over 34% at $1.88 in pre-market hours Friday on no news. On Oct.28, the company acquired Viridian Therapeutics, Inc., a privately held biotechnology company, sending the stock up more than 140%. The acquisition adds clinical stage anti-IGF-1R monoclonal antibody, VRDN-001, intended for the treatment of thyroid eye disease, to Miragen's pipeline. 2. Equillium Inc. (EQ) is up over 24% at $7.47 in pre-market hours today, adding to yesterday's gain of 10%. The company has received FDA clearance to initiate a phase III clinical trial of Itolizumab in hospitalized COVID-19 patients suffering from acute respiratory distress syndrome, dubbed EQUINOX. Enrollment in the trial is expected to begin this quarter, with initial clinical data expected mid-year 2021. 3. Genetic Technologies Limited (GENE) is up over 5% at $3.22 in pre-market hours, following an update of its business. 4. Sunesis Pharmaceuticals Inc. (SNSS) is up more than 4% at $1.22 in pre-market hours Friday on no news. The company is focused on developing SNS-510, a PDK1 inhibitor. SNS-510 is in IND-enabling studies. A 1-for-10 reverse stock split was implemented on September 3, 2020. 5. Innate Pharma S.A. (IPHA) is up over 4% at $4.10 in pre-market hours Friday. The company's lead compound is Monalizumab, which is partnered with AstraZeneca (AZN). A phase III clinical trial of Monalizumab in combination with Eli Lilly's Erbitux in patients with immuno-oncology (IO)-pre-treated recurrent or metastatic squamous cell carcinoma of the head and neck, dubbed INTERLINK-1, is underway. 6. BioNTech SE (BNTX) is up over 3% at $87.60 in pre-market hours today, adding to yesterday's gain of 9%. The company, along with Pfizer (PFE) is developing BNT162b2, a vaccine candidate against COVID-19. This vaccine candidate is currently being evaluated in a global phase III study that is underway at more than 150 clinical sites. In the Red 1. Bellicum Pharmaceuticals Inc. (BLCM) is down over 36% at $3.75 in pre-market trading Friday, on disappointing interim data from a phase I dose-escalation trial of BPX-601 in patients with relapsed/refractory metastatic pancreatic cancer. The company has priced an underwritten offering of $25 million priced at-the-market and has also announced a reduction in its workforce by 79%. 2. Axovant Gene Therapies Ltd. (AXGT) is down over 34% at $2.40 in pre-market hours today on news of a likely delay in its planned randomized, sham-controlled study of AXO-Lenti-PD gene therapy for the treatment of Parkinson's disease, dubbed EXPLORE-PD. Earlier it was expected that dosing in the EXPLORE-PD study would begin in 2021. But now, the company has said that the trial is unlikely to enroll patients by the end of 2021. 3. Cellect Biotechnology Ltd. (APOP) is down over 10% at $1.87 in pre-market hours today, giving back some of what it gained yesterday. The stock was up over 22% yesterday on news of the company entering into and commencing a collaborative development program with Sweden-based XNK Therapeutics, a pioneer in natural killer (NK) cell-based therapies. 4. Aptorum Group Limited (APM) is down more than 7% at $2.10 in pre-market hours today. Last month, the company launched Aptorum Innovations - an infectious disease liquid biopsy diagnostics subsidiary and its newly established exclusive in-licensing arrangements with Accelerate Technologies Pte Ltd - to co-develop novel molecular-based rapid pathogen identification and detection diagnostics ("RPIDD") technology. For comments and feedback contact: [email protected] Business News
PALM BEACH, FL, Oct. 27, 2020 /PRNewswire/ -- Over the years, the adoption of cloud computing in healthcare has increased owing to the rising need to curtail healthcare costs and improve the quality of healthcare and convenience for the patients. The healthcare industry often utilizes software as a service (SaaS) to increase software versatility and accessibility without having to install and run applications on multiple computers and data systems. SaaS is currently dominating the cloud computing market, especially in the healthcare industry, and as time goes by, it will only become more prevalent, according to industry observers. A recent report from one such observer, MarketsAndMarkets said that the market for healthcare cloud computing is expected to grow from USD 28.1 billion in 2020 to USD 64.7 billion by 2025, at a CAGR of 18.1% during the forecast period. Growth in the healthcare cloud computing market can be attributed to factors such as technological upgradation in healthcare industry, increasing focus on healthcare digitization and increasing deployment of cloud-based HCIT solutions by healthcare providers to improve the care process. Active companies in the markets this week include: GeoVax Labs, Inc. (NASDAQ: GOVX), ITOCO INC. (OTCPK: ITMC), AstraZeneca PLC (NASDAQ: AZN), Vir Biotechnology, Inc. (NASDAQ: VIR), Moderna, Inc., (NASDAQ: MRNA). The report added: "The COVID-19 outbreak, has upended many lives and businesses on an unprecedented scale. However, if there is one sector that has emerged stronger from this event, it would be the cloud computing industry. While many organizations are finding it difficult to run smoothly, the companies that opted for cloud computing infrastructure are functioning well. Cloud computing assists in hassle-free data storage and backup because of its scalability, and also enables one to scale back during hectic days. Moreover, the social distancing measures have mandated patients with mild symptoms to opt for remote consultation. With many healthcare providers giving consultation over video conferencing and phone calls, in place of this pandemic, the growth of healthcare cloud computing market is likely to augment considerably over the forecast period." ITOCO INC. (OTCPK: ITMC) BREAKING NEWS: ITOCO completes Immutable Virus Test Result secure web application - ITOCO has successfully developed and deployed a secure software-as-a-service (SaaS) web-based application for administering the Immutable Virus Test Result Verification System and has made it available at ImmutableTest.com. This new development, combined with the previously announced deployment of the blockchain smart contract, demonstrates the rapid progress the company is making at commercializing this important patent-pending technology. Key features of the web-based application include that it: > > Is available at www.ImmutableTest.com and within the www.ArgoBlock.com Platform Wallet. > > Enables System Administrators to add anonymized Users to the blockchain to be updated by Virus Testing Systems that are whitelisted > > Enables System Administrators to whitelist Virus Testing Systems to enable them to update virus test result data for users on the blockchain > > Provides a user interface for customers for displaying user and test result data from the blockchain as easy-to-read tables "The ImmutableTest.com application represents an accelerated step forward in bringing this patent-pending technology to market quickly," said Greg Marlin, CEO/CTO of DATANet Corp and developer of the application. "The next step in commercializing this technology is the development of the user-facing mobile application, which combines both blockchain and biometric technologies. Development has already started on this for both Android and iOS and we expect to be able to make an announcement on that shortly." "This latest technology release demonstrates our continued commitment to commercializing our technology portfolio. This web-based application technology will form an important foundation for future releases to come." said Michael Paul, CEO of ITOCO. Read more about ITMC at: https://www.itoco.net/ Other recent developments in the markets include: GeoVax Labs, Inc. (NASDAQ: GOVX) recently announced the signing of a Patent and Biological Materials License Agreement (the "License Agreement") with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), in support of GeoVax's development of a vaccine against SARS-CoV-2, the virus that causes COVID-19. The Patent License Agreement to GeoVax includes access to NIAID's patent rights in the stabilized SPIKE protein, which is the protein that SARS-CoV-2 uses to gain entry into human tissue. The License Agreement allows GeoVax to use these materials and patent rights owned by agencies of the United States Department of Health and Human Services (HHS) in combination with the Company's proprietary technology for the creation of a preventive Modified Vaccinia Ankara Virus-Virus Like Particle (MVA-VLP) vaccine that primes and/or boosts the immune system against COVID-19. The agreement provides GeoVax with nonexclusive rights to develop, manufacture and commercialize its COVID-19 vaccine. Financial terms of the License Agreement were not disclosed. AstraZeneca PLC (NASDAQ: AZN) recently announced AstraZeneca's TAGRISSO® (osimertinib) has received acceptance for its supplemental New Drug Application (sNDA) and has also been granted Priority Review in the US for the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumor resection with curative intent. While up to 30% of all patients with NSCLC may be diagnosed early enough to have potentially curative surgery, disease recurrence is still common in early-stage disease and nearly half of patients diagnosed in Stage IB, and over three quarters of patients diagnosed in Stage IIIA, experience recurrence within five years. Vir Biotechnology, Inc. (NASDAQ: VIR) recently announced the presentation of preclinical and Phase 1 data demonstrating the broad neutralizing ability, high-level effector function, extended half-life and tolerability of VIR-2482 in the prevention of influenza A. The Company also released new health economics outcomes research, which shows that elderly adults with comorbidities suffer more severe consequences of influenza. The data will be presented at IDWeek 2020, which takes place virtually Oct. 21-25. "Despite widespread influenza vaccination, the elderly in the U.S. have a high risk of hospitalization and incur significantly higher healthcare costs," said Phil Pang, M.D., Ph.D., chief medical officer of Vir Biotechnology. "The data presented at IDWeek quantify the magnitude of the urgent need for a universal influenza A-neutralizing monoclonal antibody with high efficacy. The data also suggest that VIR-2482, because of its broad influenza A strain coverage, potency and prolonged half-life, has the potential to be the first neutralizing monoclonal antibody to address this large unmet need." Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, recently announced a supply agreement with the Ministry of Public Health of Qatar for mRNA-1273, Moderna's vaccine candidate against COVID-19, to support the Ministry's ongoing efforts to secure early access to a safe and effective COVID-19 vaccine for the people of Qatar. "We appreciate the confidence of the Ministry of Health of Qatar in our mRNA vaccine platform and the collaboration we have had to date," said Stéphane Bancel, Moderna's Chief Executive Officer. "We are advancing the clinical development of mRNA-1273 with our Phase 3 COVE study, which is now fully enrolled with a representative demography of participants across ages, ethnicities and high-risk populations. In parallel we are scaling up our manufacturing capability with our strategic partners, Lonza and Rovi, to address this global health emergency by delivering a safe and effective vaccine to the people of Qatar and around the world." DISCLAIMER: FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM has been compensated twenty six hundred dollars for news coverage of the current press releases issued by ITOCO INC. by a non affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements. Contact Information: Media Contact email: [email protected] - +1(561)325-8757 SOURCE Financialnewsmedia.com
LONDON--(BUSINESS WIRE)--The new industrial synchronous belt drive market research from Technavio indicates Neutral growth in the short term as the business impact of COVID-19 spreads. Get detailed insights on the COVID-19 pandemic Crisis and Recovery analysis of the industrial synchronous belt drive market. Download free report sample "One of the primary growth drivers for this market is the Large Volume Demand from the Aftermarket,” says a senior analyst for Industrials at Technavio. The large volume demand from the aftermarket will be a significant factor driving the growth of the industrial synchronous belt drives market. Unexpected application conditions, installation errors, or the use of components that are not suitable for the operational requirements can result in faster deterioration of synchronous belt drives. The inappropriate use of drives or the improper selection of synchronous belt drives may also reduce the life of these belts. Moreover, these types of belts are often subjected to severe environmental conditions and high temperatures which may cause back cracking of the synchronous belt drive. Hence, periodic maintenance of synchronous belt drives is necessary to minimize the problems associated with the commissioning of these belt drives. End-users usually prefer to replace these belt drives as they are relatively inexpensive. The periodic maintenance activities and continuous replacement of installed drives the growth of the market. As the markets recover Technavio expects the industrial synchronous belt drive market size to grow by USD 488.87 million during the period 2020-2024. Industrial Synchronous Belt Drive Market Segment Highlights for 2020 The industrial synchronous belt drive market is expected to post a year-over-year growth rate of 2%. In the material handling segment, industrial synchronous belts help in the transport of bulk materials from one point to another. These belts are vital components in many material handling operations, especially in warehouses and global logistics. Moreover, relatively low cost, ease of installation, and availability of a wide range of sizes of industrial synchronous belt drives make them the most preferred choice in the material handling industry. This segment includes material handling through industrial synchronous belt drives in industries such as pharmaceutical and wood. The growth of these industries will support the demand for material handling equipment during the forecast period. Market growth in this segment will be faster than the growth of the market in the agriculture and mining and mineral segments. Regional Analysis 45% of the growth will originate from the APAC region. The strong demand for industrial synchronous belt drives from end-users, such as agriculture, pharmaceutical, mining and mineral, and construction material will significantly drive industrial synchronous belt drives the market growth in this region over the forecast period. China and Japan are the key markets for industrial synchronous belt drives in APAC. Market growth in this region will be faster than the growth of the market in Europe and North America. Click here to learn about report detailed analysis and insights on how you can leverage them to grow your business. Notes: The industrial synchronous belt drive market size is expected to accelerate at a CAGR of almost 4% during the forecast period. The industrial synchronous belt drive market is segmented by End-user (Material handling, Industrial machinery, Agriculture, Mining and mineral, and Others) and Geographic Landscape (APAC, North America, Europe, South Africa, and MEA). The market is fragmented due to the presence of many established vendors holding significant market share. The research report offers information on several market vendors, including AB SKF, ABB Ltd., Arntz Optibelt Group, B&B Manufacturing Inc., Bando Chemical Industries Ltd., Continental AG, Gates Industrial Corp. Plc, J. H. Fenner & Co. Ltd., Mitsuboshi Belting Ltd., and The Timken Co. Register for a free trial today to access 17,000+ market research reports using Technavio's SUBSCRIPTION platform About Us Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
CAIMEIJU采美居,为中国客户群体提供全球豪华房地产的首要网络营销平台,今天宣布与Side共同合作，联合推出Caimeiju Realty。 Tweet this “与Side的合作让Caimeiju Realty开始了这一激动人心的新篇章，”Caimeiju Realty的创始人Jeff Toth说。“我们的品牌建立在我们能够突破各种障碍，为不断增长的中国客户群体提供定制的服务。”美国和中国之间出现的新障碍正在变得复杂起来，对大多数地产公司来说都是一种挑战；尽管如此，在华人社区，买卖双方之间的在境内市场交易仍处于历史的高位。Caimeiju Realty与Side的合作关系在应对这个非常巨大而且经常被忽视的市场中具有明显的竞争优势。” 在过去的十年中,CAIMEIJU采美居在为许许多多价值数百万美元的全球豪华地产提供了有效市场广告价值， 为海外难以捉摸的中国市场提供了创新的技术和解决方案。在这新的篇章中，采美居地产将巩固其自身不断发展的同时，处于跨文化房地产市场的前沿地位。 “我们非常激动, CAIMEIJU采美居已经与Side 地产联合起来，共同加速他们的业务发展,” Guy Gal，Side首席执行官说。“Side很自豪能在简化亚裔美国人的购房和销售过程中发挥作用，并为传统上得不到充分服务的房地产专业人士创造公平的竞争环境。” Side由经验丰富的行业专业人士和世界一流的网络技术工程师带领，他们开发旨在提高每位经纪人销售力和增强客户在先进技术方面的体验。坚信拥有住房是一项基本人权的基础上，Side的使命是通过为顶级的房地产经纪人，团队和独立地产代理商提供最优秀的系统，支持并以自己的经验来更好的服务，使得每个人有不同的经验和结果，最终来实现大家共同利益。 Caimeiju, Inc 简介 自2009年起，采美居为全球顶级代理商，房地产经纪人和开发商提供定制化的豪华营销 解决方案，主要面向快速增长的中国富裕购买者和投资者。更多信息，请访问www.caimeijurealty.com Side 简介 Side将高绩效的代理商、团队和独立经纪公司转变为100%由地产经纪人拥有的成功企业和 高端品牌。Side专门与最好的地产经纪人合作，为他们提供专有技术和一流的技术团队的 支持，使他们能够提高销售产量，发展更多业务，专注于为客户服务。公司总部设在旧金山。更多信息，请访问www.sideinc.com 图片 - https://mma.prnewswire.com/media/1324482/caimeiju_realty_california_house.jpg 图标 - https://mma.prnewswire.com/media/1324483/Side_Logo.jpg Side Related Links http://www.sideinc.com SOURCE Side
On the 29th of July 2020, the CEOs of four of the biggest tech companies in the world were called to testify before the...
WASHINGTON, Oct. 30, 2020 /PRNewswire/ -- Championing America at Her Best, a Super PAC formed by a group who believe the core values of the American democratic system are in real danger, has taken the internet by storm with a series of political ads. In October, the group launched a series of hard-hitting ads attacking Donald Trump in a number of battleground states. "We launched in Michigan, Wisconsin and Arizona with major ad buys both digitally and on traditional TV, and the reception to the ads was overwhelmingly positive that we decided to launch in Iowa and North Carolina too. We clearly have a message that resonates with voters," said Founding Director of the Super PAC, Matthew Matern. "We're doing everything we can in a number of key states because we feel it's our duty to prevent the reelection of Donald Trump in the 2020 presidential election." The ads feature a Mr. Rogers lookalike who has an emotional reaction to clips of Donald Trump: one ad examines Trump's handling of the coronavirus pandemic, another attacks Trump's character with his own words, and yet another highlights just some of the misogynistic things Trump has said about women. The ads were immediately popular with Facebook and YouTube audiences, with the ads racking up close to 2 million views in just over two weeks. Voters have called the ads "amazing", "powerful", and "the best ad I've ever seen!"
USD - United States Dollar